Assyro AI

FDA Orange Book · active-ingredient family

Terlipressin acetate

Terlipressin acetate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:TERLIVAZ · NDA 022231

1

Brand (NDA)

0

Generics (ANDA)

1

Listed patents

2

Exclusivity periods

Brand (NDA) products · powder

ProductApplicantApplicationTEApproved
TERLIVAZRLDMALLINCKRODT IRELANDNDA 022231Sep 14, 2022

Marketing exclusivity (2)

  • NCENew chemical entity exclusivity (5 years)

    Sep 14, 2027

    in 1 yr 3 mo

  • ODE-406Orphan-drug exclusivity (7 years)

    Sep 14, 2029

    in 3 yr 3 mo

Listed patents (1)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10335452Apr 05, 2037in 10 yr 11 mo
U-3711

Terlipressin acetate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.